Insulet Statistics
Total Valuation
Insulet has a market cap or net worth of $17.67 billion. The enterprise value is $17.99 billion.
| Market Cap | 17.67B |
| Enterprise Value | 17.99B |
Important Dates
The next confirmed earnings date is Wednesday, February 18, 2026, before market open.
| Earnings Date | Feb 18, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Insulet has 70.35 million shares outstanding. The number of shares has decreased by -4.82% in one year.
| Current Share Class | 70.35M |
| Shares Outstanding | 70.35M |
| Shares Change (YoY) | -4.82% |
| Shares Change (QoQ) | +0.01% |
| Owned by Insiders (%) | 0.25% |
| Owned by Institutions (%) | 100.72% |
| Float | 70.11M |
Valuation Ratios
The trailing PE ratio is 72.80 and the forward PE ratio is 43.56. Insulet's PEG ratio is 1.63.
| PE Ratio | 72.80 |
| Forward PE | 43.56 |
| PS Ratio | 7.00 |
| Forward PS | 5.60 |
| PB Ratio | 12.77 |
| P/TBV Ratio | 14.40 |
| P/FCF Ratio | 41.73 |
| P/OCF Ratio | 33.12 |
| PEG Ratio | 1.63 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 35.21, with an EV/FCF ratio of 42.48.
| EV / Earnings | 73.07 |
| EV / Sales | 7.13 |
| EV / EBITDA | 35.21 |
| EV / EBIT | 42.49 |
| EV / FCF | 42.48 |
Financial Position
The company has a current ratio of 2.87, with a Debt / Equity ratio of 0.78.
| Current Ratio | 2.87 |
| Quick Ratio | 1.88 |
| Debt / Equity | 0.78 |
| Debt / EBITDA | 2.08 |
| Debt / FCF | 2.54 |
| Interest Coverage | 7.97 |
Financial Efficiency
Return on equity (ROE) is 19.68% and return on invested capital (ROIC) is 19.17%.
| Return on Equity (ROE) | 19.68% |
| Return on Assets (ROA) | 8.74% |
| Return on Invested Capital (ROIC) | 19.17% |
| Return on Capital Employed (ROCE) | 17.78% |
| Weighted Average Cost of Capital (WACC) | 11.49% |
| Revenue Per Employee | $646,615 |
| Profits Per Employee | $63,128 |
| Employee Count | 3,900 |
| Asset Turnover | 0.83 |
| Inventory Turnover | 1.65 |
Taxes
In the past 12 months, Insulet has paid $64.60 million in taxes.
| Income Tax | 64.60M |
| Effective Tax Rate | 20.79% |
Stock Price Statistics
The stock price has decreased by -9.76% in the last 52 weeks. The beta is 1.40, so Insulet's price volatility has been higher than the market average.
| Beta (5Y) | 1.40 |
| 52-Week Price Change | -9.76% |
| 50-Day Moving Average | 290.86 |
| 200-Day Moving Average | 304.88 |
| Relative Strength Index (RSI) | 24.73 |
| Average Volume (20 Days) | 955,596 |
Short Selling Information
The latest short interest is 1.98 million, so 2.81% of the outstanding shares have been sold short.
| Short Interest | 1.98M |
| Short Previous Month | 2.07M |
| Short % of Shares Out | 2.81% |
| Short % of Float | 2.82% |
| Short Ratio (days to cover) | 3.03 |
Income Statement
In the last 12 months, Insulet had revenue of $2.52 billion and earned $246.20 million in profits. Earnings per share was $3.45.
| Revenue | 2.52B |
| Gross Profit | 1.79B |
| Operating Income | 423.40M |
| Pretax Income | 310.80M |
| Net Income | 246.20M |
| EBITDA | 510.90M |
| EBIT | 423.40M |
| Earnings Per Share (EPS) | $3.45 |
Balance Sheet
The company has $757.40 million in cash and $1.08 billion in debt, with a net cash position of -$318.20 million or -$4.52 per share.
| Cash & Cash Equivalents | 757.40M |
| Total Debt | 1.08B |
| Net Cash | -318.20M |
| Net Cash Per Share | -$4.52 |
| Equity (Book Value) | 1.38B |
| Book Value Per Share | 19.68 |
| Working Capital | 1.21B |
Cash Flow
In the last 12 months, operating cash flow was $533.60 million and capital expenditures -$110.10 million, giving a free cash flow of $423.50 million.
| Operating Cash Flow | 533.60M |
| Capital Expenditures | -110.10M |
| Free Cash Flow | 423.50M |
| FCF Per Share | $6.02 |
Margins
Gross margin is 70.93%, with operating and profit margins of 16.79% and 9.76%.
| Gross Margin | 70.93% |
| Operating Margin | 16.79% |
| Pretax Margin | 12.32% |
| Profit Margin | 9.76% |
| EBITDA Margin | 20.26% |
| EBIT Margin | 16.79% |
| FCF Margin | 16.79% |
Dividends & Yields
Insulet does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 4.82% |
| Shareholder Yield | 4.82% |
| Earnings Yield | 1.39% |
| FCF Yield | 2.40% |
Analyst Forecast
The average price target for Insulet is $367.32, which is 46.21% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $367.32 |
| Price Target Difference | 46.21% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 19 |
| Revenue Growth Forecast (5Y) | 19.24% |
| EPS Growth Forecast (5Y) | 15.22% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Insulet has an Altman Z-Score of 9.07 and a Piotroski F-Score of 7.
| Altman Z-Score | 9.07 |
| Piotroski F-Score | 7 |